吉林長龍藥業(08049.HK)前三季度淨利8302.7萬元 同比減少5.77%
格隆匯 11 月 13日丨吉林長龍藥業(08049.HK)公佈,截至2020年9月30日止9個月,公司營業額4.4億元人民幣,同比減少6.69%;公司擁有人應占溢利8302.7萬元,同比減少5.77%;每股盈利14.8分。
公司加大了硬件改造力度,對小容量注射劑車間、凍乾粉針劑車間、前處理提取車間、針劑原料車間進行升級改造,購置新型設備,提高了生產能力,滿足市場供應需求。
新建固體化藥車間,完成了設備構建及調試工作,用於厄貝沙坦片、非布司他片和二甲雙胍複方製劑等仿製藥的研發與一致性評價,公司產品目錄不斷豐富,提高了公司的研發能力和市場競爭力,目前厄貝沙坦片已完成藥學研究。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.